10.15 USD
-0.13
1.26%
At close Apr 30, 4:00 PM EDT
1 day
-1.26%
5 days
-1.26%
1 month
-1.36%
3 months
6.06%
6 months
3.57%
Year to date
7.52%
1 year
18.99%
5 years
39.04%
10 years
39.04%
 

About: Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Employees: 24,622

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

358% more call options, than puts

Call options by funds: $3.53M | Put options by funds: $770K

42% more first-time investments, than exits

New positions opened: 95 | Existing positions closed: 67

29% more capital invested

Capital invested by funds: $5.45B [Q3] → $7B (+$1.56B) [Q4]

17% more repeat investments, than reductions

Existing positions increased: 202 | Existing positions reduced: 172

3% more funds holding

Funds holding: 578 [Q3] → 597 (+19) [Q4]

2.45% more ownership

Funds ownership: 5.65% [Q3] → 8.11% (+2.45%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for HLN.

Financial journalist opinion

Based on 4 articles about HLN published over the past 30 days

Negative
Proactive Investors
23 hours ago
Haleon shares hit by weaker US vitamin sales
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 1% after the toothpaste and painkillers maker reported slightly stronger first-quarter growth than expected but saw a weaker performance than expected from its vitamins, minerals and supplements (VMS) arm in America.  The FTSE 100 group posted a Q1 update showing 3.5% organic revenue growth, supported by positive contributions from all product categories and regions, beating an average City forecast of 3.3%.
Haleon shares hit by weaker US vitamin sales
Negative
Reuters
1 day ago
Haleon reports lower first-quarter revenue hurt by a weaker flu season
British consumer healthcare group Haleon on Wednesday reported a 2.3% fall in its first-quarter revenue as sluggish demand for its cold and cough medicines outside of North America continued to weigh.
Haleon reports lower first-quarter revenue hurt by a weaker flu season
Positive
Reuters
2 weeks ago
UK's Haleon takes full control of Chinese consumer healthcare venture
British consumer healthcare group Haleon said on Tuesday it has gained complete ownership of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake for about 1.62 billion yuan ($221.4 million).
UK's Haleon takes full control of Chinese consumer healthcare venture
Positive
Proactive Investors
3 weeks ago
Does defensive Haleon have a cure for the current market blues?
Citi believes Haleon PLC (LSE:HLN, NYSE:HLN) is well positioned for the current uncertain climate, describing the consumer healthcare group as a solid defensive play for investors concerned about recession risks and the fallout from Donald Trump's new tariff regime. Shares in the maker of household brands such as Sensodyne and Panadol, have been under pressure amid broader worries over US consumer demand and a tough comparison with last year's strong flu season.
Does defensive Haleon have a cure for the current market blues?
Positive
Seeking Alpha
1 month ago
Haleon: A Defensive Play That Makes Sense Amidst The Stock Market Sell-Off
As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding margins and further debt reduction on a net debt/adjusted EBITDA basis (now 2.8x from 4.0x) demonstrate financial strength in uncertain economic conditions. Robust dividend coverage (2.5x covered by earnings) with steady growth and the strategic streamlining of its portfolio highlights Haleon as a reliable defensive investment.
Haleon: A Defensive Play That Makes Sense Amidst The Stock Market Sell-Off
Neutral
Proactive Investors
1 month ago
Haleon buys £170m of shares as Pfizer offloads final stake
Haleon PLC (LSE:HLN, NYSE:HLN) has bought roughly £170 million of its shares back from former parent company Pfizer Inc (NYSE:PFE, ETR:PFE).   The FTSE 100-listed maker of toothpaste and vitamins paid 385p per share for the off-market purchase, which is part of a previous agreement when Haleon was spun out in 2022 that its former parent companies, GSK being the other, would eventually cut their stakes.
Haleon buys £170m of shares as Pfizer offloads final stake
Neutral
Reuters
1 month ago
Pfizer sells entire Haleon stake for $3.24 billion
Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said on Wednesday.
Pfizer sells entire Haleon stake for $3.24 billion
Neutral
Reuters
1 month ago
Pfizer to dispose of entire Haleon stake
Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday.
Pfizer to dispose of entire Haleon stake
Positive
Seeking Alpha
1 month ago
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, with a low forward multiple and management's commitment to maintaining dividends. Cost savings and Haleon share sales should support Pfizer's dividend yield, with free cash flow expected to improve next year.
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs
Positive
Seeking Alpha
1 month ago
Haleon: Growing Profits And Dividend
I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by free cash flow, but the 1.6% yield is less attractive compared to peers. The balance sheet is manageable with net debt at 22% of market cap, though I question the optimality of share buybacks at current prices.
Haleon: Growing Profits And Dividend
Charts implemented using Lightweight Charts™